Antiretrovirals and other HIV-related regimens: unit prices and volume
Export Indicator
The average unit prices of antiretroviral regimens and other HIV-related regimens for a country’s HIV programme and the associated procurement volume.
The average unit prices and procurement volume of HIV commodities help monitor the market dynamics of antiretroviral based prevention, treatment regimens and other HIV-related regimens and support the process of triangulating with people reported to be on antiretroviral therapy and monitor the scaleup and procurement costs of PrEP regimens.
Not applicable
Not applicable
Data type
The average unit price per pack of regimen in current US$ or the local currency units for the reporting year, and the absolute number of packs procured within a given period.
Not applicable
Procurement and supply chain management systems
Data collection tools
Logistics Management Information Systems (LMIS)
To ensure clarity in reporting, the average unit price should reflect the landing cost of the product at the central warehouse. This means:
- Include: Product cost plus freight, insurance, and any international handling charges up to the point of delivery at the central warehouse.
- Exclude: All in-country supply chain costs, such as storage, distribution to facilities, and last-mile delivery.
Annually
- By funding source (domestic, international)
- By PrEP modality (oral PrEP, long-acting Cabotegravir, long-acting Lenacapavir, and any other approved forms).
- By antiretroviral treatment regimens
- By regimens used for treatment of Advanced HIV Disease
The procurement supply chain management systems (PSM) in countries maintain information on health commodity procurement at the central level. In some countries, there are LMIS that monitor commodities data at the level of the health facility. These information systems may be able to provide the data for reporting on this indicator.
For more information on this indicator, please see Annex 4 of the Global AIDS Monitoring (GAM) guidelines.
For more information on the background and guidance to reporting, with emphasis on in-country collaboration and process, please see the Global AIDS Monitoring Framework 2022-2026.